High-Intensity Statin versus Upfront Equivalent-Dose Combination of Moderate-Intensity Statin with Ezetimibe
Eun Ho Choo1, Chan Joon Kim2, Byung-Hee Hwang1
1Seoul St.Mary's Hospital, The Catholic University of Korea, Seoul, Korea (the Republic of).
BMJ Open
|November 6, 2025
Summary
Moderate-intensity statin with ezetimibe offers comparable LDL-C reduction to high-intensity statin after acute myocardial infarction (AMI). This combination may provide a safer alternative for patients with AMI.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- High-intensity statin therapy is the standard for lowering low-density lipoprotein cholesterol (LDL-C) post-acute myocardial infarction (AMI).
- Combining moderate-intensity statin with ezetimibe presents a potential alternative for LDL-C reduction.
- This approach may offer similar efficacy with a potentially improved safety profile compared to high-intensity statins.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy.
- To compare LDL-C reduction and clinical outcomes in patients following AMI.
Main Methods:
- The ROSUZET-AMI trial is a multicentre, prospective, open-label, randomised, non-inferiority study.
- Patients with AMI post-percutaneous coronary intervention were randomised to receive either rosuvastatin 5mg with ezetimibe 10mg or rosuvastatin 20mg.
- The primary endpoint included cardiovascular death, major coronary events, or non-fatal stroke.
Main Results:
- The study is ongoing, and results are pending.
- Data collection and analysis are in progress.
Conclusions:
- The study aims to determine if a moderate-intensity statin and ezetimibe combination is non-inferior to high-intensity statin monotherapy.
- Findings will inform clinical practice regarding lipid-lowering strategies after AMI.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.0K
07:40Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
Published on: October 10, 2019
7.7K
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
01:30Acute Coronary Syndrome III: Diagnostic Studies
200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
01:28Acute Coronary Syndrome IV: Interprofessional Care
205
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
205
01:30Acute Coronary Syndrome I: Introduction
753
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
753
01:26Angina IV: Management
223
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
223